- Home
- TSHA vs SHEN Comparison
TSHA vs SHEN Comparison
Compare TSHA & SHEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- SHEN
- Stock Information
- Founded
- TSHA 2019
- SHEN 1902
- Country
- TSHA United States
- SHEN United States
- Employees
- TSHA N/A
- SHEN N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- SHEN Telecommunications Equipment
- Sector
- TSHA Health Care
- SHEN Telecommunications
- Exchange
- TSHA Nasdaq
- SHEN Nasdaq
- Market Cap
- TSHA 728.4M
- SHEN 673.1M
- IPO Year
- TSHA 2020
- SHEN N/A
- Fundamental
- Price
- TSHA $2.46
- SHEN $13.91
- Analyst Decision
- TSHA Strong Buy
- SHEN Strong Buy
- Analyst Count
- TSHA 7
- SHEN 1
- Target Price
- TSHA $7.57
- SHEN $26.00
- AVG Volume (30 Days)
- TSHA 5.2M
- SHEN 324.8K
- Earning Date
- TSHA 08-11-2025
- SHEN 08-06-2025
- Dividend Yield
- TSHA N/A
- SHEN 0.71%
- EPS Growth
- TSHA N/A
- SHEN N/A
- EPS
- TSHA N/A
- SHEN N/A
- Revenue
- TSHA $7,224,000.00
- SHEN $346,708,000.00
- Revenue This Year
- TSHA N/A
- SHEN $13.32
- Revenue Next Year
- TSHA N/A
- SHEN $7.77
- P/E Ratio
- TSHA N/A
- SHEN N/A
- Revenue Growth
- TSHA N/A
- SHEN 27.84
- 52 Week Low
- TSHA $1.05
- SHEN $9.77
- 52 Week High
- TSHA $3.31
- SHEN $21.89
- Technical
- Relative Strength Index (RSI)
- TSHA 45.90
- SHEN 62.24
- Support Level
- TSHA $2.48
- SHEN $13.78
- Resistance Level
- TSHA $2.66
- SHEN $14.39
- Average True Range (ATR)
- TSHA 0.21
- SHEN 0.40
- MACD
- TSHA -0.06
- SHEN 0.08
- Stochastic Oscillator
- TSHA 10.14
- SHEN 72.77
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About SHEN Shenandoah Telecommunications Co
Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.